UCB: psoriasis drug superior to Novartis' in study
(CercleFinance.com) - Belgium's UCB said on Friday that its drug bimekizumab is more effective than a rival medicine from Novartis, having met the primary endpoint of a late-stage study in adults with moderate-to-severe plaque psoriasis.
The phase III study, involving 743 participants who had been suffering from psoriasis for at least six months, showed bimekizumab was superior to Novartis' Cosentyx for complete skin clearance at both weeks 16 and 48, UCB said.
The study hence met its primary endpoint with statistical significance, and also met all secondary endpoints, the Belgian drugmaker said.
UCB shares, however, were down almost 3% on Friday morning on Euronext Brussels.
"There is tough competition in immunoinflammation," analysts at UBS said, pointing out that Novartis can remain the biggest player in the field.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The phase III study, involving 743 participants who had been suffering from psoriasis for at least six months, showed bimekizumab was superior to Novartis' Cosentyx for complete skin clearance at both weeks 16 and 48, UCB said.
The study hence met its primary endpoint with statistical significance, and also met all secondary endpoints, the Belgian drugmaker said.
UCB shares, however, were down almost 3% on Friday morning on Euronext Brussels.
"There is tough competition in immunoinflammation," analysts at UBS said, pointing out that Novartis can remain the biggest player in the field.
Copyright (c) 2020 CercleFinance.com. All rights reserved.